In addition to INO-3107, Inovio has made significant strides with its proprietary DNA-encoded monoclonal antibody (DMAb ... functional antibodies against COVID-19, with notable durability lasting ...

The company’s proprietary technology platforms, including its DNA-encoded monoclonal antibody (DMAb ... DMAb Platform and COVID-19 Antibodies Inovio’s DMAb platform has shown promising ...

In addition to INO-3107, Inovio has made significant strides with its proprietary DNA-encoded monoclonal antibody (DMAb) platform. Recent clinical data has demonstrated the platform’s ability to ...

The company’s proprietary technology platforms, including its DNA-encoded monoclonal antibody (DMAb) platform ... DMAb Platform and COVID-19 Antibodies Inovio’s DMAb platform has shown promising ...

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Regeneron and Sanofi’s PD-1 inhibitor Libtayo ... pipeline despite the recent close attention to the German biotech’s coronavirus candidate, partnered with Pfizer. It is one of five FixVacc ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The following is a list of major prescription drugs whose ingredients or components are imported into the United States from the European Union, based on U.S. Food and Drug Administration import data ...